Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
The disialoganglioside GD2 is a tumor-associated antigen that may allow for the application of targeted immunotherapies (anti-GD2 antibodies, GD2 CAR T cells) in patients with neuroblastoma and other solid tumors. We retrospectively investigated GD2 expression in a breast cancer cohort, using immuno...
Guardado en:
Autores principales: | Ramona Erber, Sareetha Kailayangiri, Hanna Huebner, Matthias Ruebner, Arndt Hartmann, Lothar Häberle, Julia Meyer, Simon Völkl, Andreas Mackensen, Laura Landgraf, Carol I. Geppert, Rüdiger Schulz-Wendtland, Matthias W. Beckmann, Peter A. Fasching, Nicole Farwick, Claudia Rossig, Paul Gass |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/559414f8e53e4331963a4808b821cd01 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Monoclonal Antibody Therapies for High Risk Neuroblastoma
por: Furman WL
Publicado: (2021) -
ORDERED L-FUZZY Gd-EXTREMALLY DISCONNECTED SPACES AND TIETZE EXTENSION THEOREM
por: ROJA,E, et al.
Publicado: (2008) -
Glypican-1-antibody-conjugated Gd-Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer
por: Huang X, et al.
Publicado: (2018) -
SwinGD: A Robust Grape Bunch Detection Model Based on Swin Transformer in Complex Vineyard Environment
por: Jinhai Wang, et al.
Publicado: (2021) -
Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer
por: Wu Y, et al.
Publicado: (2020)